Short answer
EyePoint, Inc. (EYPT) filed its fiscal 2025 10-K annual report with the SEC on Mar 5, 2026. It reported revenue of $31M (−27.5% year over year) and net income of −$232M.
- Top risk flagged: DOJ investigation under False Claims Act and Anti-Kickback Statute with $4.7M proposed settlement plus corporate integrity agreement, finalization expected H1 2026
FY2025 key financial metrics · XBRL
- Revenue
- $31M
- −27.5% YoY
- Net income
- −$232M
- −77.2% YoY
- Operating margin
- -776.0%
- −438.9 pp YoY
- EPS (diluted)
- −$3.17
- −36.6% YoY
- ROE
- -75.8%
- −36.9 pp YoY
- Operating cash flow
- −$240M
- −90.2% YoY
Source: XBRL data from the EyePoint, Inc. (EYPT) FY2025 10-K on SEC EDGAR. USD.
EyePoint, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Clinical-stage biopharma developing sustained intraocular drug delivery therapeutics for serious retinal diseases leveraging proprietary bioerodible Durasert E™ technology
- New emphasized product: DURAVYU™, a novel multi-mechanism VEGF receptor, PDGF, and IL-6/JAK1 inhibitor in Phase 3 trials for wet AMD and DME, first patient dosed in DME Phase 3 in Feb 2026
- Strategic shift: Transition from early to pivotal late-stage global Phase 3 trials with enrollment completion in two wet AMD studies (LUGANO, LUCIA) and initiation of two DME studies (COMO, CAPRI)
- Quantitative metric: Over 900 patients enrolled across two Phase 3 wet AMD trials, additional ~480 patients planned for Phase 3 DME trials; Phase 2 VERONA trial showed +10.3 letters BCVA improvement in subgroup vs +3.0 aflibercept
- Noteworthy fact: DURAVYU's intracellular multi-MOA acting on VEGF receptors plus anti-inflammatory IL-6 signaling constitutes a new treatment paradigm with potential 6-month sustained delivery reducing treatment burden by over 85%
Management Discussion & Analysis
- Revenue $31.4M down 28% YoY from $43.3M; product sales fell 50% to $1.6M, license/collab revenues down 57% to $16.7M, royalty income up 708% to $13.0M
- Operating expenses $274.8M up 45% YoY from $189.1M; R&D $221.0M up 66%, G&A $51.6M down 1%; operating loss $243.4M vs $145.9M, loss margin ~776% vs 337% (loss/net loss ÷ revenue)
- Best segment: Royalty income $13.0M (+708%); Worst: License/collab revenue down $21.8M to $16.7M
- Financing: Raised $172.5M via public offering + $11.6M ATM sales; cash and securities $306.1M at year-end; Operating cash outflow $240.1M; no buybacks or dividends disclosed
- Outlook: Phase 3 DURAVYU trials enrollment complete, data expected mid-2026; first DME patient dosed Feb 2026; settled DOJ investigation in principle with ~$4.7M payment; cash runway into Q4 2027
Risk Factors
- DOJ investigation under False Claims Act and Anti-Kickback Statute with $4.7M proposed settlement plus corporate integrity agreement, finalization expected H1 2026
- Clinical trial delay risk: DURAVYU Phase 3 topline data expected in 2026, cash runway extends only into Q4 2027
- Manufacturing risk: inability to scale DURAVYU production could delay Phase 3 trials and commercialization
- Competitive risk: approval and market acceptance of DURAVYU may be impacted by alternative wet AMD treatments and generics
- Liquidity risk: $306.1M cash runway likely sufficient only through Q4 2027, requiring uncertain future capital raises that may dilute shareholders
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.